

Josep M Gatell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4648214/josep-m-gatell-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71
papers

2,652
citations

25
h-index

51
g-index

79
ext. papers

3,059
ext. citations

5.3
avg, IF

4.09
L-index

#	Paper	IF	Citations
71	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2380-2393	5.1	2
70	A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 83, 479-485	3.1	0
69	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3334-3343	5.1	3
68	Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. <i>Antiviral Therapy</i> , 2019 , 24, 425-435	1.6	12
67	Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2019 , 88, 73-79	10.5	2
66	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019 , 68, 597-606	11.6	18
65	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 151-159	0.9	4
64	Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review. <i>Antiviral Therapy</i> , 2019 , 24, 393-404	1.6	4
63	Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. <i>Aids</i> , 2018 , 32, 1309-1316	3.5	4
62	Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1965-1971	5.1	32
61	Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 16-20	0.9	4
60	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 268-276	0.9	5
59	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. <i>Aids</i> , 2018 , 32, 2533-2545	3.5	50
58	Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. <i>HIV Clinical Trials</i> , 2017 , 18, 49-53		
57	Utility of Systematic Isolation of immune cell subsets from HIV-infected individuals for miRNA profiling. <i>Journal of Immunological Methods</i> , 2017 , 442, 12-19	2.5	7
56	New challenges in therapeutic vaccines against HIV infection. <i>Expert Review of Vaccines</i> , 2017 , 16, 587-602	3.0	22
55	Tolerability of integrase inhibitors in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1752-1759	5.1	67

54	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. <i>Aids</i> , 2017 , 31, 2503-2514 ^{3.5}	45
53	Imbalance in mitochondrial dynamics and apoptosis in pregnancies among HIV-infected women on HAART with obstetric complications. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2578-2586	5.1 7
52	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017 , 35, 88-99	0.9 6
51	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2857-2861	5.1 6
50	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. <i>PLoS ONE</i> , 2017 , 12, e0186602	3.7 11
49	Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 829-836	5.1 7
48	Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. <i>Journal of Leukocyte Biology</i> , 2016 , 99, 349-59	6.5 15
47	Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1125-7 ^{5.1}	5
46	Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4(+) T-cell activation and dendritic cell maturation. <i>Immunology and Cell Biology</i> , 2016 , 94, 689-700	7
45	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1982-6	5.1 6
44	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1987-93	5.1 8
43	Backbones versus core agents in initial ART regimens: one game, two players. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 856-61	5.1 14
42	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 361-71	0.9 10
41	Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1975-81	5.1 35
40	Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1578-1585	11.6 4
39	Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2015 , 15, 785-92	25.5 111
38	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. <i>Journal of Virology</i> , 2015 , 89, 9189-99	6.6 28
37	Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015 , 33, 156-65	0.9 11

36	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1833-42	5.1	47
35	Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial. <i>Clinical Infectious Diseases</i> , 2015 , 60, 811-20	11.6	25
34	Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort. <i>PLoS ONE</i> , 2015 , 10, e0145701	3.7	18
33	Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant <i>Staphylococcus aureus</i> : a multicenter clinical trial. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1105-12	11.6	57
32	Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1653-9	5.1	18
31	Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naïve adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 68, 1750-8	25.5	120
30	Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naïve HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19532	5.4	46
29	Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014 , 1, 14017	6.4	13
28	Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. <i>PLoS ONE</i> , 2014 , 9, e114142	3.7	18
27	Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19246	5.4	13
26	Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19773	5.4	2
25	Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19603 ⁴	5.4	3
24	Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. <i>PLoS ONE</i> , 2014 , 9, e87334	3.7	11
23	A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. <i>Science Translational Medicine</i> , 2013 , 5, 166ra2	17.5	168
22	Therapeutic vaccines against HIV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2012 , 8, 569-81	4.4	50
21	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011 , 9, 208	8.5	124
20	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. <i>Nature Medicine</i> , 2010 , 16, 460-5	50.5	441
19	When and why to start antiretroviral therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 383-5	5.1	7

18	Assessment of migration of HIV-1-loaded dendritic cells labeled with 111In-oxine used as a therapeutic vaccine in HIV-1-infected patients. <i>Immunotherapy</i> , 2009 , 1, 347-54	3.8	7
17	The use of integrase inhibitors in treatment-experienced patients. <i>European Journal of Medical Research</i> , 2009 , 14 Suppl 3, 30-5	4.8	6
16	Future of HIV-1 therapy: new drugs, new targets and new strategies. <i>Future HIV Therapy</i> , 2007 , 1, 5-7		
15	In Vivo Effects of Highly Active Antiretroviral Therapies Containing the Protease Inhibitor Nelfinavir on Mitochondrially Driven Apoptosis. <i>Antiviral Therapy</i> , 2005 , 10, 945-951	1.6	10
14	Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 36, 823-30	3.1	63
13	Mitochondrial Effects of Antiretroviral Therapies in Asymptomatic Patients. <i>Antiviral Therapy</i> , 2004 , 9, 47-55	1.6	44
12	Immune Restoration in HIV-Positive, Antiretroviral-Naive Patients after 1 Year of Zidovudine/Lamivudine plus Nelfinavir or Nevirapine. <i>Antiviral Therapy</i> , 2004 , 9, 197-204	1.6	6
11	Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy. <i>Antiviral Therapy</i> , 2004 , 9, 979-985	1.6	3
10	A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. <i>Aids</i> , 2003 , 17, 43-51	3.5	37
9	Mitochondrial Dna Depletion and Respiratory Chain Enzyme Deficiencies are Present in Peripheral Blood Mononuclear Cells of HIV-Infected Patients with Haart-Related Lipodystrophy. <i>Antiviral Therapy</i> , 2003 , 8, 333-338	1.6	44
8	Effects of Metformin Or Gemfibrozil on the Lipodystrophy of HIV-Infected Patients Receiving Protease Inhibitors. <i>Antiviral Therapy</i> , 2003 , 8, 403-410	1.6	21
7	Genotypic and Phenotypic Resistance Patterns in Early-Stage HIV-1-Infected Patients Failing Initial Therapy with Stavudine, Didanosine and Nevirapine. <i>Antiviral Therapy</i> , 2002 , 7, 283-287	1.6	5
6	Lipodystrophy syndrome in patients with HIV infection: quality of life issues. <i>Drug Safety</i> , 2001 , 24, 157-66	3.1	64
5	The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. <i>Aids</i> , 2001 , 15, F29-40	3.5	138
4	Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. <i>Aids</i> , 2000 , 14, 1921-33	3.5	69
3	Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. <i>Aids</i> , 1999 , 13, F79-86	3.5	200
2	Risk Factors for Nosocomial Bacteremia in a Large Spanish Teaching Hospital: A Case-Control Study. <i>Infection Control and Hospital Epidemiology</i> , 1991 , 12, 150-156	2	17
1	Lymphocyte subpopulations in Spanish parenteral drug addicts. <i>Scandinavian Journal of Infectious Diseases</i> , 1986 , 18, 71-8		6

